Auris Medical (EARS) Trading Down 18.2%
Auris Medical Holding AG (NASDAQ:EARS) shares fell 18.2% during trading on Monday . The company traded as low as $0.35 and last traded at $0.36. 4,817,269 shares were traded during mid-day trading, an increase of 161% from the average session volume of 1,844,024 shares. The stock had previously closed at $0.44.
A number of research firms recently commented on EARS. Zacks Investment Research cut Auris Medical from a “buy” rating to a “hold” rating in a report on Monday, January 21st. ValuEngine raised Auris Medical from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Roth Capital assumed coverage on Auris Medical in a report on Thursday, December 20th. They set a “buy” rating and a $5.00 price objective on the stock.
The firm has a market capitalization of $14.74 million, a PE ratio of -0.06 and a beta of -0.57.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/auris-medical-ears-trading-down-18-2/2813616.html.
Auris Medical Company Profile (NASDAQ:EARS)
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Further Reading: What are convertible shares?
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.